Arcellx is a biotechnology company reimagining cell therapy through the development of immunotherapies. Co.'s D-Domain powered autologous and allogeneic Chimeric Antigen Receptor T cells (CAR-Ts) includes classical single infusion CAR-Ts (ddCARs) and dosable and controllable universal CAR-Ts (ARC-SparX), to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. Co.'s main ddCAR product candidate, CART-ddBCMA, is for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). Co. is developing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia and myelodysplastic syndrome. The ACLX YTD return is shown above.
The YTD Return on the ACLX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACLX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACLX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|